AI-Designed Fibrosis Drug Shows Potential for Biological Age Reversal

An analysis of blood samples from a Phase IIa study suggests that rentosertib, an AI-designed drug for idiopathic pulmonary fibrosis, may lower biological age in patients.

Researchers from Hong Kong-based Insilico Medicine profiled blood proteins from 42 participants and utilized six different aging clocks to measure the drug's impact alongside its primary treatment function.

The findings, published in Nature Biotechnology, indicate that the drug, originally developed for a scarring lung condition typically affecting those around age 65, shows signs of biological age reversal.